Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Post-Marketing Study of Cilostazol (Cilostazol Stroke Prevention Study 2)
This study is ongoing, but not recruiting participants.
Study NCT00234065 Information provided by Otsuka Pharmaceutical Co., Ltd.
First Received: October 4, 2005 Last Updated: April 23, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cerebral Infarction
Additional conditions recognized in this trial
Infarction
Stroke
More general conditions related to this trial
Brain Diseases
Brain Infarction
Brain Ischemia
Cardiovascular Diseases
Central Nervous System Diseases
Cerebrovascular Disorders
Ischemia
Necrosis
Nervous System Diseases
Pathologic Processes
Vascular Diseases
Interventions listed in this trial
Cilostazol
Aspirin
More general drug interventions related to this trial
Analgesics
Analgesics, Non-Narcotic
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antirheumatic Agents
Autonomic Agents
Bronchodilator Agents
Cardiovascular Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Fibrin Modulating Agents
Fibrinolytic Agents
Hematologic Agents
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Phosphodiesterase Inhibitors
Physiological Effects of Drugs
Platelet Aggregation Inhibitors
Protective Agents
Respiratory System Agents
Sensory System Agents
Therapeutic Uses
Vasodilator Agents
Sponsors listed in this trial
Otsuka Pharmaceutical Co., Ltd.
Back to top of Main Content
